Search - tctmd.com

Displaying 21 - 40 of 555

Sort: Relevancy | Date

Presentation TCT 2024

TCT 486: Ultrasound Based Renal Denervation Reduces Blood Pressure in Patients With Chronic Kidney Disease: Results of a Multicenter Prospective Randomized Sham-Controlled Blinded Investigator Initiated Trial

Presenter: Roland Schmieder

October 28, 2024

Presentation TCT 2024

TCT 485: Device-Related Adverse Events and Modes of Failure Related to Renal Denervation Systems: Insights From Analysis of the FDA MAUDE Database

Presenter: Manasa Jasti

October 28, 2024

Presentation TCT 2024

TCT 484: Twelve Week Safety and Efficacy of a Novel Extravascular Bi-lateral Renal Denervation Device in a Porcine Model at Nominal Dose

Presenter: Abraham Tzafriri

October 28, 2024

Presentation TCT 2024

TCT 483: One Year Follow-Up Effect of Renal Sympathetic Denervation After Percutaneous Coronary Intervention in Patients With Resistant Hypertension and Type 2 Diabetes Mellitus

Presenter: Daria Feshchenko

October 28, 2024

Presentation TCT 2024

TCT 482: Anatomical Predictors for Blood Pressure Outcome After Endovascular Ultrasound Renal Denervation

Presenter: Karl Fengler

October 28, 2024

Presentation TCT 2024

TCT 481: Renal Artery Imaging Through Long-Term Follow-Up Following Radiofrequency Renal Denervation: Results From the SPYRAL Clinical Trial Program

Presenter: Felix Mahfoud

October 28, 2024

Presentation TCT 2024

TCT 480: Blood Pressure Reductions by Radiofrequency Renal Denervation Procedural Characteristics: Pooled 24-Month Results From the SYMPLICITY Clinical Program

Presenter: Felix Mahfoud

October 28, 2024

Presentation TCT 2024

The Body of Evidence: Safety, Efficacy and Sustainability of rf RDN

Presenter: Felix Mahfoud

October 28, 2024

Presentation TCT 2024

Setting the Standard: Patient Selection &the Safe and Effective Use of RDN

Presenter: Tai Kobayashi

October 28, 2024

Presentation TCT 2024

RDN Care Pathway Development

Presenter: Raven Voora

October 28, 2024

Presentation TCT 2024

Hypertension State of Union and Role of RDN

Presenter: Roxana Mehran

October 28, 2024

Presentation TCT 2024

Case Examples and Outcomes

Presenter: Tai Kobayashi

October 28, 2024

News Conference News TCT 2024

Radiation Survey Reveals Variable Practices as Operators Look to Themselves for Fixes

L.A. McKeown

October 27, 2024

Presentation TCT 2024

Digital Era in Dermatology with Noninvasive Virtual Skin Biopsies (Enspectra Health) (69301)

Presenter: Gabriel Sanchez

October 27, 2024

Presentation TCT 2024

Too Good to Be True? Five Top Lessons of Major GLP-1 Agonists Trials

Presenter: C. Michael Gibson

October 27, 2024

Presentation TCT 2024

How Great if True: My Futuristic View in How GLP-1 Agonist Will Continue Expanding Its Therapeutic Reach

Presenter: Marc Bonaca

October 27, 2024

News Opinion Editor's Corner TCT 2024

What’s Going to Be Big at TCT 2024?

Michael O'Riordan

October 17, 2024

News Conference News TCT 2023

RADIANCE: 'Modest' Renal Denervation Effect Remains at 6 Months

Todd Neale

October 31, 2023

Presentation TCT 2023

Con

Presenter: Celina Yong

October 26, 2023

Presentation TCT 2023

Pro

Presenter: Sandeep Nathan

October 26, 2023

Advertisement

TCT 486: Ultrasound Based Renal Denervation Reduces Blood Pressure in Patients With Chronic Kidney Disease: Results of a Multicenter Prospective Randomized Sham-Controlled Blinded Investigator Initiated Trial

TCT 485: Device-Related Adverse Events and Modes of Failure Related to Renal Denervation Systems: Insights From Analysis of the FDA MAUDE Database

TCT 484: Twelve Week Safety and Efficacy of a Novel Extravascular Bi-lateral Renal Denervation Device in a Porcine Model at Nominal Dose

TCT 483: One Year Follow-Up Effect of Renal Sympathetic Denervation After Percutaneous Coronary Intervention in Patients With Resistant Hypertension and Type 2 Diabetes Mellitus

TCT 482: Anatomical Predictors for Blood Pressure Outcome After Endovascular Ultrasound Renal Denervation

TCT 481: Renal Artery Imaging Through Long-Term Follow-Up Following Radiofrequency Renal Denervation: Results From the SPYRAL Clinical Trial Program

TCT 480: Blood Pressure Reductions by Radiofrequency Renal Denervation Procedural Characteristics: Pooled 24-Month Results From the SYMPLICITY Clinical Program

The Body of Evidence: Safety, Efficacy and Sustainability of rf RDN

Setting the Standard: Patient Selection &the Safe and Effective Use of RDN

RDN Care Pathway Development

Hypertension State of Union and Role of RDN

Case Examples and Outcomes

Radiation Survey Reveals Variable Practices as Operators Look to Themselves for Fixes

Digital Era in Dermatology with Noninvasive Virtual Skin Biopsies (Enspectra Health) (69301)

Too Good to Be True? Five Top Lessons of Major GLP-1 Agonists Trials

How Great if True: My Futuristic View in How GLP-1 Agonist Will Continue Expanding Its Therapeutic Reach

What’s Going to Be Big at TCT 2024?

RADIANCE: 'Modest' Renal Denervation Effect Remains at 6 Months

Con

Pro

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content